Seidel, Ronald D.
Merazga, Zohra
Thapa, Dharma Raj
Soriano, Jonathan
Spaulding, Emily
Vakkasoglu, Ahmet S.
Ruthardt, Paige
Bautista, Wynona
Quayle, Steven N.
Kiener, Peter A.
Low, Simon
Ross, John F.
Cemerski, Saso
Suri, Anish
Almo, Steven C.
Chaparro, Rodolfo J.
Article History
Received: 11 June 2021
Accepted: 6 September 2021
First Online: 28 September 2021
Competing interests
: Initial work underlying the Immuno-STATâ„¢ technology was performed in the laboratory of S.C.A., of which S.C.A., R.S. and R.C. are co-founders and are co-inventors on SynTac Polypeptides and Uses Thereof (PCT/2015/195531 and corresponding patents and applications), which are licensed to Cue Biopharma, Inc. and relate to the Immuno-STAT platform. R.S., R.C., S.L and J.R. are co-inventors of other patents and patent applications that are owned by Cue Biopharma, Inc. and relate to the Immuno-STAT and Neo-STATâ„¢ platforms. S.C.A., R.S., A.S and R.C. are stockholders in Cue Biopharma, Inc.; R.S., Z.M., J.S., P.R., W.B., S.Q., J.F. and A.S. are employee's of Cue Biopharma, Inc. All other co-authors declare no competing interest.